Log In
Print
BCIQ
Print
Print this Print this
 

MGA271

  Manage Alerts
Collapse Summary General Information
Company MacroGenics Inc.
DescriptionHumanized mAb against CD276 (B7-H3) with an optimized Fc region
Molecular Target B7-H3 (CD276)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat patients with B7-H3-expressing solid tumors
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$1,550.0M

$40.0M

$1,000.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today